Share on StockTwits

Epizyme (NASDAQ:EPZM) EVP Robert A. Copeland sold 10,830 shares of Epizyme stock on the open market in a transaction dated Monday, August 18th. The stock was sold at an average price of $36.07, for a total transaction of $390,638.10. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on EPZM shares. Analysts at HC Wainwright raised their price target on shares of Epizyme from $40.00 to $45.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Epizyme from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 7th. They now have a $36.80 price target on the stock. Finally, analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.

Shares of Epizyme (NASDAQ:EPZM) traded down 0.15% during mid-day trading on Thursday, hitting $33.48. The stock had a trading volume of 7,357 shares. Epizyme has a 52 week low of $18.10 and a 52 week high of $42.71. The stock has a 50-day moving average of $32.28 and a 200-day moving average of $27.27. The company’s market cap is $1.124 billion.

Epizyme (NASDAQ:EPZM) last released its earnings data on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.50) by $0.10. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $7.59 million. On average, analysts predict that Epizyme will post $-1.62 earnings per share for the current fiscal year.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.